FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Real-time Bid/Ask 12:16:17 04/06/2024 BST | ||
| 8.63 EUR / 8.64 EUR | -0.29% |
|
| Current month | -0.69% | ||
| 1 month | -24.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 8.66 | -0.69% |
| 31/05/24 | 8.72 | -2.90% |
| 30/05/24 | 8.98 | -0.55% |
| 29/05/24 | 9.03 | +1.46% |
| 28/05/24 | 8.9 | +1.60% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 07:28 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG01QC |
| ISIN | DE000MG01QC7 |
| Date issued | 11/03/2024 |
| Strike | 1,232 kr |
| Maturity | Unlimited |
| Parity | 4.7 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.78 € |
|---|---|
| Lowest since issue | 8.26 € |
| Spread | 0.01 € |
| Spread % | 0.12% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
923.9
DKK
Average target price
917.3
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- Certificat
